Skip to main content

Table 2 Risk of bias in a randomized trial and non-randomized studies of anti-Ebola therapies

From: Anti-Ebola therapy for patients with Ebola virus disease: a systematic review

Agent
Citation
Bias arising from the randomization process Bias due to confounding Bias in selection of participants Bias in classification of interventions Bias due to deviations from intended interventions Bias due to missing outcome data Bias in outcomes measurement Bias in selection of results reported Overall risk of bias
Randomized clinical trial
ZMapp
PREVAIL II Writing Group, 2016 [24]
Low N/A N/A N/A Some concerns Low Low Low Low
Non-randomized single-arm intervention study with concurrent controls
TKM-130803
Dunning et al., 2016 [25]
N/A Moderate Moderate Low Low Low Low Low Moderate
Convalescent whole blood
Sahr et al., 2017 [26]
N/A Moderate Low to moderate Moderate Moderate Low Low Low Moderate
Interferon β-1a
Konde et al., 2017 [27]
N/A Moderate to serious Low Moderate to low Low Low Low Low Moderate
Non-randomized, single-arm, intervention study with historical control
Convalescent plasma
van Griensven et al., 2016 [28]
N/A Serious Moderate Low Low Low Low Low Moderate
Favipiravir
Sissoko et al., 2016 [29]
N/A Serious to critical Low Low Moderate Low Low Low Moderate
Favipiravir
Bai et al., 2016 [30]
N/A Serious Moderate Moderate Moderate Moderate Moderate Low Moderate
Non-randomized single-arm intervention study without controls
Brincidofovir
Dunning et al., 2016 [31]
N/A Critical Low to moderate Low Moderate Low Low Low Moderate
Retrospective cohort study
Artesunate-amodiaquine
Gignoux et al., 2016 [32]
N/A Moderate to serious Moderate Moderate Low Low Low Low Moderate
  1. Abbreviations: N/A not applicable